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ed with palliative chemotherapy at Samsung Medical Center, Seoul, 
Korea were retrospectively reviewed. According to a case-match-con-
trol study design, 334 patients matched by age, sex, and histology for 
each treatment period; pre-geﬁtinib era (1999-2001) and post-geﬁtinib 
era (2002-2005) were selected and compared for overall survival. For 
each group, 69.5% were male, 53.3% were < 60 years, and 66.5% of 
patients had adenocarcinoma. 
Results: With the median follow-up of 68 and 30 months in pre- and 
post-geﬁtinib eras, the median overall survival (OS) from the date of 
ﬁrst diagnosis of advanced/metastatic or recurrent disease were 11.5 
(95% CI, 10.0-12.9 months) and 19.3 (95% CI, 17.2-21.3 months) 
months, respectively, which was signiﬁcantly different (p<0.001). The 
overall response rate and disease control rate were 24.7% (3 complete 
response, 73 partial response) and 48.7% for 308 evaluable post-geﬁ-
tinib era patients, respectively. By multivariate analysis for all the 668 
patients, geﬁtinib treatment (HR 0.64, P<0.001), Stage III (HR 0.64, 
P<0.001), PS ≤1 (HR 0.57, P<0.001), adenocarcinoma histology (HR 
0.80, P=0.025), and prior chemotherapy ≤2 (HR 0.66, P<0.001) were 
signiﬁcant favorable predictors for survival . Exploratory subgroup 
analyses also showed a prolonged overall survival for patients in 
post-geﬁtinib era in almost all subgroups: age <60 (12.7 vs 20.6 M, 
P<0.001). age ≥60 (10.6 vs 18.1 M, P<0.001), male (11.4 vs 16.5 M, 
P<0.001), female (12.4 vs 25.1 M, P<0.001), never-smokers (12.6 vs 
24.9 M, P<0.001), smokers (10.9 vs 15.7 M, P<0.001), stage III (14.2 
vs 24.7 M, P<0.001), stage IVRecurrent (9.9 vs 17.6 M, P<0.001), 
adenocarcinoma histology (12.6 vs 24.2 M, P<0.001), performance 
status (PS) ≤1 (12.7 vs 20.4, P<0.001), prior chemotherapy ≥1 (11.7 vs 
20.0 M, P<0.001), and previous platinum based chemotherapy (11.7 vs 
20.3 M, P<0.001). 
Conclusions: This historical control study shows signiﬁcant improve-
ment of overall survival with the introduction of geﬁtinib in clinic to 
the treatment of advanced/metastatic NSCLC patients. These results 
strongly suggest the efﬁcacy as well as the survival advantage of 
EGFR tyrosine kinase inhibitor in Asian population for the treatment of 
advanced NSCLC. 
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Background: Data suggest that following treatment with erlotinib at 
150 mg/d, current smokers have lower exposure, experience less rash 
and achieve less survival beneﬁt than former or never smokers. It has 
been hypothesized that this may be due, in part, to induction of CYP 
enzymes by tobacco use and that a higher dose of erlotinib, if feasible, 
may improve outcome in current smokers. 
Methods: A 2-part study was initiated to escalate erlotinib to the Maxi-
mum Tolerated Dose (MTD) in current smokers and evaluate pharma-
cokinetics (PK) at this MTD versus 150 mg/d. Part I: sequential cohorts 
of advanced NSCLC patients (pts) that were current smokers received 
escalating doses of erlotinib for 14 days until MTD was deﬁned. Part 
II: pts were randomized between the MTD and 150 mg/d erlotinib and 
PK assessed at D14. 
Results: Twenty-two pts were enrolled in Part I at 4 dose levels; 200, 
250, 300 and 350 mg/d. Dose limiting toxicities were observed in 1/6 
MTD-evaluable pts at 300 mg/d (G3 rash) and 2/5 pts at 350 mg/d (G3 
acneiform dermatitis and G3 fatigue/decreased ECOG PS). Thirteen pts 
have been entered into Part II to date, 7 randomized to 300 mg/d and 
6 to 150 mg/d. Median age is 59 yrs (range 52-74) with 7 males and 
6 females. Histology: Adenocarcinoma (7/13), Squamous (5/13) and 
other (1/13). Median/range number of cigarettes smoked and duration 
of smoking is 15/d (10-25) and 42 yrs (20-63), respectively. Erlotinib 
dose of 300 mg/d has been well tolerated to date, with a single case 
of G3 diarrhea. Other toxicity among all 13 pts has been grade 1 or 2, 
mainly skin toxicity (46%) and diarrhea (31%). Preliminary PK data 
(n=10) show median plasma Cmax of erlotinib was 1.77 (range 0.85-
4.58) versus 3.48 (range 1.14-4.88) ug/mL for 150 and 300 mg/d dose 
cohorts, respectively. The median AUCTau of erlotinib was 29.3 (range 
19.8-50.9) versus 46.2 (range 23.7-95.2) ug.hr/mL for 150 and 300 
mg/d dose cohorts, respectively. PK of the main metabolite of erlotinib, 
OSI-420, mirrored erlotinib PK. The median trough plasma concentra-
tion at steady state (CminSS) of erlotinib was 0.42 and 1.84 ug/mL for 
150 and 300 mg/d dose cohorts, respectively. 
Conclusions: The MTD of erlotinib in NSCLC pts who continue to 
smoke was 300 mg/d. Early data indicate that there is a dose-dependent 
increase in the systemic erlotinib exposure in current smokers. Enroll-
ment in to Part II continues and updated data will be presented.
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Erlotinib was approved for funding as a systemic therapy treatment for 
third line management of advanced NSCLC by the BC Cancer Agency 
(BCCA) in April 2004. BCCA patient outcome and cost data are 
routinely collected to verify the therapeutic effectiveness and cost-ef-
fectiveness of systemic treatment policies.
This was a pragmatic retrospective analysis of all patients who received 
third line erlotinib compared to a historical group treated with second 
line docetaxel then no further active treatment, both according to BCCA 
protocol. The primary end-point was cost-effectiveness, measured in 
terms of cost-per-life-year-gained. Secondary end-points included: 
median overall survival (MOS); overall survival (OS) at one year; and 
comparison to phase III efﬁcacy results. Data was retrieved from the 
Cancer Agency Information System (CAIS) and Systemic Therapy Data 
Warehouse. Life-years-gained were calculated from the area under the 
survival function curve. CEA took the BCCA perspective and costs 
included all direct drug costs for treatment of advanced disease. Sensi-
tivity analyses included varying life expectancy across its 95% CI, cost 
